ArticlePloS one2026
Multi-level determinants of tuberculosis treatment completion in rural Uganda: A cross-sectional study.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTuberculosis (TB) treatment completion rates in high-burden countries like Uganda often fall short of the WHO End TB Strategy target of ≥90%. This study evaluated multilevel determinants of treatment completion to guide evidence-based improvement strategies in rural Western Uganda.
methodsWe conducted a cross-sectional, multi-center analytical study of 224 patients with drug-susceptible TB across four public health facilities in Kakumiro District. Eligible participants had been on treatment for at least six months. Data collected via structured questionnaires were validated against facility TB registers. Multivariable logistic regression identified independent predictors, reported as adjusted odds ratios (AOR) with 95% confidence intervals (CI).
resultsThe treatment completion rate was 82.6% (185/224), with a 30.4% TB-HIV co-infection rate. Significant positive predictors included high TB knowledge (AOR = 14.0; 95% CI: 3.06-24.5), high economic status (AOR = 7.2; 95% CI: 1.63-31.5), belief in treatment efficacy (AOR = 6.2; 95% CI: 2.02-18.8), and respectful health worker behavior (AOR = 5.0; 95% CI: 2.15-11.83). Community-level support was critical, specifically religious/community leader advocacy (AOR = 4.2; 95% CI: 1.84-9.51) and community health worker (CHW) home visits (AOR = 3.5; 95% CI: 1.64-7.72). Waiting time less than 30 minutes (AOR = 6.3, 95% CI: 1.91-20.96) also positively impacted TB treatment completion. Major negative predictors were male gender (AOR = 0.3; 95% CI: 0.11-0.86), drug stockouts (AOR = 0.3; 95% CI: 0.11-0.70), belief in traditional cures (AOR = 0.3; 95% CI: 0.13-0.71), and stigma (AOR = 0.4; 95% CI: 0.16-0.80).
conclusionAchieving the WHO End TB targets requires integrated, multilevel interventions. Efforts should focus on male-targeted engagement, strengthening supply chains to eliminate drug stockouts, enhancing CHW-led community outreach, and reducing stigma to ensure equitable treatment success.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.